In all, 85% of Ewing's sarcoma family tumors (ESFT), a neoplasm of unknown histogenesis, express EWS-FLI1 transcription factor gene fusions. To characterize direct target genes avoiding artificial model systems, we cloned genomic DNA from ESFT chromatin precipitating with EWS-FLI1. We now present a comprehensive list of 99 putative transcription factor targets identified, for the first time, by a hypothesis-free approach based on physical interaction. Gene-derived chromatin fragments co-precipitating with EWS-FLI1 were nonrandomly distributed over the human genome and localized predominantly to the upstream region and the first two introns of the genes. At least 20% of putative direct EWS-FLI1 targets were neural genes. One-third of genes recovered showed a significant ESFT-specific expression pattern and were found to be altered upon RNAi-mediated knockdown of EWS-FLI1. Among them, MK-STYX, encoding a MAP kinase phosphatase-like protein, was consistently expressed in ESFT. EWS-FLI1 was found to drive MK-STYX expression by binding to a single ETS binding motif within the first gene intron. MK-STYX serves as precedence for successful recovery of direct EWS-FLI1 targets from the authentic ESFT cellular context, the most relevant system to study oncogenic mechanisms for the discovery of new therapeutic targets in this disease.
Introduction
Ewing's sarcoma family tumors (ESFT) are characterized in about 85% of cases by a reciprocal chromosomal translocation fusing the human ETS oncogene FLI1 to the EWS gene . As a result, a chimeric protein is expressed, which is commonly assumed to act as an aberrant transcription factor (Ohno and Reddy, 1993; Bailly et al., 1994; Lessnick et al., 1995) . So far, the study of EWS-FLI1 downstream pathways has been largely restricted to heterologous cell types ectopically expressing the fusion protein since the tissue of origin for ESFT is still unknown. Gene expression profiling in different model systems revealed an almost equal number of genes suppressed as activated in response to ectopic EWS-FLI1 expression (Arvand et al., 2001; Dauphinot et al., 2001; Lessnick et al., 2002; Rorie et al., 2004) . Several potential candidates have been described as being specifically affected by EWS-FLI1. These include genes encoding cytoskeletal and extracellular matrix proteins as well as proteins involved in their degradation Fuchs et al., 2003; Matsui et al., 2003) , several genes involved in intra-or extracellular signaling (Thompson et al., 1996; May et al., 1997; Hahm et al., 1999; Im et al., 2000; Deneen et al., 2003a; Watanabe et al., 2003; Fuchs et al., 2004) , and cell cycle regulation and senescence (Watson et al., 1997; Arvand et al., 1998; Dauphinot et al., 2001; Lessnick et al., 2002; Deneen et al., 2003a; Nakatani et al., 2003; Takahashi et al., 2003) . For few genes (MNFG, PIM-3) forced expression has been shown to support transformation of NIH3T3 cells (May et al., 1997; Deneen et al., 2003b) . The differential screening methods applied in these studies did not allow discrimination between direct and indirect targets of EWS-ETS chimeric proteins. In addition, depending on the model system, EWS-FLI1 expression resulted in diverse cell-type-specific physiological outcomes ranging from cell death or growth arrest (Deneen and Denny, 2001; Lessnick et al., 2002) to blocked or altered differentiation (Teitell et al., 1999; Eliazer et al., 2003; Torchia et al., 2003; Rorie et al., 2004) or transformation (May et al., 1993b; Lessnick et al., 1995) , while certain non-NIH3T3 fibroblast cell lines appeared not to be affected by EWS-FLI1 expression at all (May et al., 1993a) . These functional discrepancies are reflected by differences in putative EWS-FLI1 target gene expression patterns as demonstrated recently for PDGF-c (Zwerner et al., 2003) . As a consequence, only few candidate genes (TGFbR2, ID-2, TNC, UPP-1) have been confirmed as directly regulated by EWS-ETS fusion proteins in ESFT so far (Hahm et al., 1999; Im et al., 2000; Nishimori et al., 2002; Deneen et al., 2003a; Fukuma et al., 2003; Watanabe et al., 2003) .
In order to identify direct EWS-FLI1 target genes by a hypothesis-free approach, which is independent of the mode of gene regulation, we chose chromatin immunoprecipitation (ChIP) (Weinmann and Farnham, 2002) to enrich for and clone genomic DNA associated with EWS-FLI1 in the authentic ESFT cellular context.
Results

A dual ChIP approach enriches for EWS-FLI1-specific target sequences
To precipitate EWS-FLI1-containing chromatin complexes, specific antibodies against the C-terminal FLI1 and the N-terminal EWS portions were used in two successive rounds of ChIP. Control precipitations were performed in the absence of an antibody and in the presence of an irrelevant antibody of the same isotype (anti-KAI1). ChIP experiments were performed in the ESFT cell line STA-ET-7.2, which lacks germline EWS and FLI1 expression (Kovar et al., 2001) .
Genomic DNA was directly cloned from EWS-FLI1-containing chromatin complexes. Control precipitates were equally treated. About 400 insert-containing clones were obtained for the specific antibodies as opposed to 100 and 50 clones for the unrelated antibody sample and the no-antibody control, respectively. Inserts larger than 150 bp were sequenced; 278, 49, and 10 clones obtained from ChIP with EWS-FLI1 specific, irrelevant and no antibody were analysed in detail.
Nonspecific precipitation of DNA fragments would be expected to result in about 20% of gene hits, as this is the percentage of genomic DNA covered by genes according to the draft human genome sequence. Reminiscent of a random precipitation, the frequency of gene-derived clones obtained from ChIP with the irrelevant antibody was 18% (9/49), and in the sample precipitated in the absence of any antibody, only 1 of 10 cloned fragments was derived from a gene. In contrast, EWS-FLI1-specific antibodies specifically enriched in gene hits (including 10 kb of upstream and downstream sequences) with a frequency of 39% (108/278). Nine genes were hit twice. Since no amplification reaction has been performed before cloning, these clones represent independent hits. Thus, we identified a total of 99 genes as potential EWS-FLI1 binders (Table 1) .
Genomic assignments of EWS-FLI1-specific ChIP clones
The chromosomal localizations of the 170 EWS-FLI1-associated intergenic clones largely followed the proportional genomic share of the individual chromosomes considering their size and number in the published karyotype of the STA-ET-7.2 cell line (Hattinger et al., 1999) . This suggests a random distribution that is compatible with nonspecific precipitation (data not shown). In contrast, the chromosomal distribution of the 99 genes co-precipitating with the EWS-FLI1-specific antibodies did not reflect the chromosomal gene content, with an over-representation of genes encoded on chromosomes 3 and 8. Otherwise, genes hit by EWS-FLI1-specific ChIP were found on all chromosomes except 14, 21, and 22 (data not shown). Figure 1 illustrates the intragenic distribution of genederived fragments cloned from the EWS-FLI1-specific ChIP samples. In all, 12 of the 99 cloned gene fragments localized to the upstream region (up to 10 kb from exon 1); 27 and 18 fragments were derived from introns/exons 1 and 2, respectively. Thus, 58% of EWS-FLI1-specific intragenic ChIP clones localized to gene regions likely involved in transcriptional regulation.
Regulation of EWS-FLI1-specific genes by RNAimediated suppression of EWS-FLI1
The impact of EWS-FLI1 binding on expression of its putative direct target genes was studied in STA-ET-7.2 cells after modulation of EWS-FLI1 by RNA interference (RNAi). Two specific small interfering (si) RNAs, one targeting the fli1 3 0 coding region (EF4) and one targeting the fusion region of type 2 ews-fli1 RNA (EF22), the variant expressed in STA-ET-7.2 cells, as well as a type 1 fusion-specific siRNA (EF30) were designed and cloned as small hairpin (sh) precursor RNA encoding cassettes into the retroviral vector pSR. As demonstrated in Figure 2 , shRNAs targeting type 2 EWS-FLI1 efficiently interfered with growth of STA-ET-7.2 cells. In monolayer cultures (Figure 2a ), doubling times for shRNA-silenced cells were more than 4 days, while control-infected cells doubled within about 24 h. Colony formation of EWS-FLI1-silenced cells in soft agar was completely suppressed. Even after 11 days postinfection (8 days after plating), no multicellular colonies were observable, while control-infected cells efficiently formed colonies comprising more than four cells at a frequency of 2.7%. However, 2 days later, when the number of control-infected colonies was 5.8 per 100 seeded cells, small colonies were also observed in shEF4-and shEF22-infected cells at a frequency of 0.1%, indicating that EWS-FLI1 silencing did not eradicate the cells (not shown). Figures 2c and d demonstrate efficient suppression of EWS-FLI1 expression by the construct shEF4 6 days after retroviral infection of STA-ET-7.2 cells and its effect on the regulation of known EWS-FLI1 downstream genes. Concomitant with EWS-FLI1 modulation, expression of TGFbR2 and p57
KIP2
, two genes known to be suppressed in the presence of EWS-FLI1, increased dramatically, and CCND1 expression decreased. Similar results were obtained with the construct shEF22 (data not shown).
Affymetrix GeneChip analysis was conducted in STA-ET-7.2 cells using the HG-U133A and B microarrays to study the influence of EWS-FLI1 suppression on the expression of the putative EWS-FLI1 target genes obtained by ChIP. Three independent comparisons were performed between EWS-FLI1-suppressed (shEF4 and shEF22) and mismatch (shEF30) or empty control vector (pSR)-containing cells. To validate the functional effect of EWS-FLI1 suppression, we investigated changes in expression of the established target genes TGFbR2 and TNC (Figure 3a ). As expected, tnc mRNA Presentation of ChIP-derived genes (a) down-and (b) upregulated upon EWS-FLI1 knockdown in STA-ET-7.2 cells, and (c) of genes whose expression was either not affected by EWS-FLI1 modulation, not detectable or below threshold, or not represented on the Affymetrix microarray. Genes obtained more than once by ChIP are indicated ( # ). For EWS-FLI1 knockdown, three independent RNAi experiments were performed comparing shEF4 (targeting the fli1 3 0 coding RNA portion) with shEF30 (mismatched control), shEF4 with empty vector control, and shEF22 (targeting the ews-fli1 type 2 fusion region) with shEF30 6 days after infection of STA-ET-7.2 cells. In (a) and (b), mean values (M) for the fold changes and standard deviations (s.d.) are shown, except for KIAA1432 present on the HG-U133B array only, which was tested only once (*). For each gene, the chromosomal assignment, the localization of ChIP-derived fragments in either the upstream region (up), downstream region (down), exon (ex) or intron (int) of the respective genes, and the putative function are indicated. Except for the genes not represented on the U95Av2 array (-), the expression of the individual genes in ESFT as compared to other small blue round cell tumors is presented as the median of signal intensities on Affymetrix HG-U95Av2 obtained from seven ESFT divided by the median of signal intensities for all non-ESFT samples including six osteosarcomas, eight neuroblastomas, and six clear-cell sarcomas. If a gene was represented by more than one probe set on the U95A-chip ( + ), mean values of all these probe sets were calculated first Direct EWS-FLI1 target genes C Siligan et al modulation of EWS-FLI1 (Table 1c ). In contrast, 18 and 15 genes were found to be down-and upregulated by RNAi-mediated EWS-FLI1 suppression, respectively ( Figure 3b and c). Although changes in the expression of these genes in individual experiments were low ranging from 1.3-to 5.9-fold, they were highly reproducible between the two different EWS-FLI1-specific shRNAs in the three independent experiments performed (Table  1a and b). Therefore, it is unlikely that the results obtained for target genes with low expression levels arise from background noise. Similar results were obtained in ESFT cell lines TC252 and SK-N-MC, which express type 1 EWS-FLI1 in a germline EWS-positive background using shEF30 for RNAi (data not shown). Thus, at least 33 genes identified by our ChIP screen were found to be affected in expression by EWS-FLI1 in ESFT cells.
Expression pattern of putative direct EWS-FLI1 target genes in small round cell tumors
Previously, we monitored the expression pattern of seven ESFT cell lines in comparison to six osteosarcoma, eight neuroblastoma, and six clear-cell sarcoma of soft parts samples on Affymetrix HG-U95Av2 microarrays, which include probe sets for 58 of the genes isolated by ChIP (Schaefer et al., 2004) . Of these genes, we found 16 and 12 down-and upregulated upon repression of EWS-FLI1, respectively (Table 1) . Categorizing the expression values of each of these genes as either higher (median (ESFT)/median (non-ESFT)>1) or lower (median (ESFT)/median (non-ESFT)o1) in the ESFT versus the non-ESFT samples, we observed a significant correlation between genes generally activated in ESFT and genes which are downregulated upon EWS-FLI1 modulation and, vice versa, genes expressed at low level in ESFT and genes activated by EWS-FLI1 deprivation (P ¼ 0.0037, w 2 test).
Confirmation of in vivo binding of EWS-FLI1 to candidate target genes by ChIP and PCR
To confirm the association of EWS-FLI1 with chromatin at the cloned genomic regions, independent ChIP experiments followed by PCR with primers flanking the cloned sequences were performed for a subset of four candidate target genes whose expression changed upon EWS-FLI1 knockdown in STA-ET-7.2 cells to different extents. After two rounds of ChIP, amplification products were specifically obtained from either EWS or FLI1 antibody precipitations for the tested genes ACCN1, MK-STYX, TCF12, and PFTK1, providing further evidence for the direct in vivo interaction of EWS-FLI1 with these genes (Figure 4 ).
EWS-FLI1 binds to the MK-STYX gene which is abundantly expressed in ESFT
ETS proteins generally bind to the core consensus binding motif GGAA/T. This sequence was also found to be present in one to several copies in all the DNA fragments cloned from EWS-FLI-specific ChIP reactions. One of the isolated candidate EWS-FLI1 targets, MK-STYX, contained six canonical ETS recognition sequences within the precipitated genomic fragment from the first intron of the gene. MK-STYX encodes for a phosphatase-dead dual specificity phosphatase-like protein implicated in the regulation of MAP kinases (Wishart and Dixon, 1998) In all, 57% of fragments align to the upstream regions (12 fragments), and the first and second intron (27 and 18, respectively) of the genes Direct EWS-FLI1 target genes C Siligan et al down into three subfragments, MK1, MK2, and MK3, each containing pairs of the ETS recognition motif (Figure 5a ), which were subjected to electromobility shift assays (EMSAs) with EWS-FLI1. A TGFbR2 promoter fragment was used as a positive control. Using recombinant EWS-FLI1 protein alone, no EWS-FLI1-specific protein-DNA complexes were detectable. The addition of an FLI1 antibody greatly stimulated binding of EWS-FLI1 to the TGFbR2 promoter and the MK2 fragment ( Figure 5b ). Similar results were obtained for recombinant factor Xa-digested GST-EWS-FLI1 protein and EWS-FLI1 immunopurified from STA-ET-7.2 and SK-N-MC cells (Figure 5c ). The need for antibody binding to allow protein-DNA interaction in vitro may reflect the requirement for cellular protein interactions absent from the in vitro reaction (Staal et al., 1996) . Unlabeled double-stranded MK2 and TGFbR2 oligonucleotides efficiently competed for complex formation with EWS-FLI1, while an unrelated competitor (HRAS) did not, confirming the specificity of the MK2 complexes for EWS-FLI1 (Figure 5c and d) . Mutating the second GGAA motif (mk2-2) of fragment MK2 (MK2-2m competitor) significantly reduced its ability to compete for EWS-FLI1 binding, whereas the MK2-1m fragment with a mutation of the first motif mk2-1 was similarly effective in competition as wild-type MK2, (Figure 5d ). EMSAs using the two mutated fragments MK2-1m and MK2-2m as probes confirmed the requirement for an intact mk2-2 site, since mutation of mk2-2 but not of mk2-1 significantly reduced binding of EWS-FLI1 to DNA. These results confirm that a single ETS binding motif is sufficient for binding of EWS-FLI1.
EWS-FLI1 regulates the expression of MK-STYX in vivo
Quantification of MK-STYX expression in the absence or presence of EWS-FLI1-specific shRNA by real-time PCR confirmed the microarray results. When EWS-FLI1 expression was suppressed by 86%, tgfbr2 levels increased sevenfold in STA-ET-7.2 cells. Concomitantly, an 80% reduction in mk-styx RNA was revealed (Figure 6a) . Similar results were obtained in the ESFT cell line SK-N-MC (data not shown).
To test directly the functional consequences of EWS-FLI1 interaction with MK-STYX, the 163 bp genomic fragment isolated by ChIP was used in reporter gene assays in the neuroblastoma cell line SJ-NB-7 (Figure 6b Table 1a and b
Direct EWS-FLI1 target genes C Siligan et al methyl ketone (z-VAD.fmk), resulting in a further threefold increase in reporter gene activity (Figure 6b , lower panel). MK-STYX promoter-driven luciferase expression was also increased upon forced expression of ectopic EWS-FLI1 within the ESFT context (STA-ET-7.2, Figure 6c ). Upon cotransfection of shEF4 to counteract EWS-FLI1 expression, but not of the mismatched shEF4M control vector, reporter induction was reversed. ShEF4, but not shEF4M, also suppressed basal reporter gene activity in STA-ET-7.2 cells, compatible with endogenous EWS-FLI1 being responsible for constitutive MK-STYX promoter activity in ESFT cells. These results provide functional confirmation for successful isolation of direct EWS-FLI1 target genes by our dual ChIP approach.
Discussion
Ectopic expression models for the study of transcription factor function in heterologous cells harbor a major disadvantage: they do not account for the authentic cellular context that may affect accessibility of chromatin to the factor and influence selection and regulation of potential targets. In addition, target gene regulation may depend on the level of expression of the regulatory protein of interest. We therefore approached the problem of target identification for the ESFT-specific translocation product EWS-FLI1 by a combination of two methods, ChIP and RNAi, targeting endogenous EWS-FLI1 directly in ESFT cells. The list of candidate EWS-FLI1 binding genes obtained has to be considered as incomplete since none of the previously established target genes was obtained and out of 99 genes cloned only nine genes were hit more than once. Of this list, 55 genes are represented on the HG-U95Av2 microarray used in a study of inducible ectopic EWS-FLI1 expression in hTERT-immortalized human fibroblasts (Lessnick et al., 2002) . In this transgenic model system, 13 and eight genes were up-and downregulated, respectively, but only 12 genes overlapped with the set of 33 genes affected by modulation of EWS-FLI1 in ESFT. Of these, four genes (ACCN1, PCCA, PFTK1, SLC2A2) showed upregulation upon EWS-FLI1 induction in the fibroblast model and downregulation upon EWS-FLI1 suppression in ESFT cells. In the RNAi experiments targeting EWS-FLI1 in ESFT cells, the fold change in expression of EWS-FLI1-specific candidate genes cloned from ChIP products was low but highly reproducible, while the genes most affected by EWS-FLI1 suppression showed an up to 200-fold change in microarray analyses (not shown). In a biological system, a slight change in the expression of a gene upstream of a signal transduction cascade may lead to a multiplication of the signal in the downstream hierarchy. Trisomy of chromosome 8, which appeared to be enriched in putative EWS-FLI1 target genes, occurs with a frequency of about 50% in ESFT and may be envisaged as a mechanism to further increase the dosage of EWS-FLI1-specific genes (Hattinger et al., 2002) .
It is noteworthy that only 12% of ChIP clones were derived from the upstream regulatory regions, while 45% derived from the first two introns. Although there are examples for bona fide transcription factors, which bind to their targets preferentially in introns, this finding may as well point to functions distinct from mere transcriptional regulation. Increasing evidence suggests that pre-mRNA splicing takes place cotranscriptionally. EWS fusion proteins have been demonstrated to alter splice site selection in experimental systems and to interfere with YB-1-mediated splicing (Chansky et al., 2001; Ohkura et al., 2002) . YB-1 links transcription to RNA processing, being normally recruited to the RNA polymerase II complex via interaction with germline EWS or its close relative TLS. In ESFT cells that express EWS-FLI1, this linkage was found to be defective. For the ETS transcription factor SPI1/PU1, which interacts with TLS abrogating its function in splice site selection as well (Hallier et al., 1998) , evidence was obtained that the splicing effect depends on the ETS DNA-binding domain together with the transactivation domain implicating a role for direct DNA binding in this Confirmation of the in vivo interaction between EWS-FLI1 and four candidate target genes in an independent ChIP experiment. PCR on ChIP products from four genes, one upregulated (TCF12) and three downregulated (ACCN1, MK-STYX, and PFTK1) to different extents upon knock down of EWS-FLI1, obtained by two successive rounds of immunoprecipitation from STA-ET-7.2 cells. The TGFbR2 gene promoter, which is downregulated by EWS-FLI1, served as a control for the ChIP reactions. Amplification products were obtained when EWS-FLI1-specific antibodies (C19 or 139/2) but not irrelevant (anti-KAI) or no antibody were used. Input, PCR from isolated chromatin before precipitation Direct EWS-FLI1 target genes C Siligan et al process (Delva et al., 2004) . Intriguingly, many of the candidate target genes of EWS-FLI1 identified by our ChIP approach are known to be expressed in a multitude of differently initiated and/or spliced variants in different tissues. Therefore, it will be interesting to study the isoform expression pattern for each individual putative EWS-FLI1 target, whose overall expression was only moderately or not affected in response to EWS-FLI1 suppression.
Among the genes that showed an ESFT-specific expression pattern when compared to other small blue round cell tumors of childhood is the tumor suppressor DLG2, a membrane-associated guanylate kinase homologue that interacts with protein 4.1 in epithelial cells and in the presynaptic neuron. Notably, several other genes arising from our EWS-FLI1-specific ChIP screen including PCLO, NCAM1, NPY and CNTNAP2 play roles in this cell type as well. Altogether, expression of at least one-fifth of genes precipitating with EWS-FLI1-specific antibodies has been described as being associated with neural tissue. This finding is intriguing since ESFT show limited neural differentiation, which has previously been taken as an argument for neural histogenesis of the disease. However, the partial neural differentiation potential of ESFT may be linked to EWS-FLI1-mediated deregulation of neural target genes.
We focused on MK-STYX as an example for a gene isolated by ChIP and only moderately affected by EWS-FLI1-directed RNAi to demonstrate binding of and regulation by EWS-FLI1. Interestingly, the site recognized by EWS-FLI1 very closely resembled that of the TGFbR2 gene, a previously confirmed EWS-FLI1 probes: In vitro binding of EWS-FLI1 to putative ETS core consensus sites in the first intron of MK-STYX. (a) Probes used for EMSA with recombinant EWS-FLI1. A TGFbR2 promoter fragment and a fragment of the first intron of HRAS were used as positive and negative controls, respectively. Three probes (MK1, MK2, MK3) containing the six putative ETS consensus binding sites mk1-1, mk1-2, mk2-1, mk2-2, mk3-1, and mk3-2 (in bold) were generated to delineate the region of interaction with EWS-FLI1 within the 163 bp fragment from the first intron of the MK-STYX gene cloned by the dual ChIP approach. In probes MK2-1m and MK2-2m, the putative ETS binding motifs mk2-1 and mk2-2 were mutated from GGAA to GGGG (underlined). (b) EMSA with recombinant EWS-FLI1 (recEWS-FLI1) and TGFbR2, MK1, MK2, and MK3 as probes in the absence and presence of FLI1-specific monoclonal antibody Hyb7.3 demonstrating binding of MK2 to EWS-FLI1 but only in the presence of FLI1 antibody. The right panel presents a slightly compressed view of the whole gel demonstrating the absence of any protein-DNA complex in the absence of FLI1 antibody. (c) EMSA with endogenous EWS-FLI1 immunopurified from STA-ET-7.2 and SK-N-MC cells (IP) as compared to recEWS-FLI1 using MK2 as radioactively labeled probe in the absence or presence of a 10-fold excess of cold-specific competitor and FLI1 antibody. In the presence of FLI1 antibody, endogenous EWS-FLI1 from ESFT cells formed specific complexes with MK2 similar to recEWS-FLI1. A slightly slower migration of complexes with ESFT-expressed EWS-FLI1 may be caused by post-translational modifications absent in recEWS-FLI1 (data not shown). (d) Upper panel: Binding of recEWS-FLI1 to MK2 in the presence of FLI antibody and a 100-, 10-, and twofold excess of cold probes TGFbR2, HRAS, MK2, MK2-1m, or MK2-2m as competitors. Only TGFbR2, MK2, and MK2-1m were capable of efficiently competing for complex formation with EWS-FLI1 suggesting mk2-2 as binding site for EWS-FLI1. Lower panel: EMSA using MK2 and mutant MK2-1m and MK2-2m probes. Only MK2 and MK2-1m formed complexes with EWS-FLI1 compatible with mk2-2 being responsible for binding of EWS-FLI1 to MK2 Direct EWS-FLI1 target genes C Siligan et al target, indicating a preference for the sequence ACAG-GAAA. MK-STYX belongs to the family of MAP kinase phosphatases but lacks enzymatic activity due to an amino-acid exchange in the active center of the protein. The actual function of STYX proteins is not known. It is suggested that they bind to phosphorylated kinases, thereby preventing dephosphorylation by active phosphatases keeping the kinases in an active state. It will therefore be of great interest to study the influence of EWS-FLI1 on the MAP kinase pathway in ESFT in more detail. However, STYX proteins may also serve alternative functions by complexing with other phosphorylated proteins such as CRHSP-24, an RNAbinding protein implicated in translational repression of histone mRNAs and involved in differentiation of spermatids (Wishart and Dixon, 2002) . So far, our results for MK-STYX provide proof of principle for the relevance of a combined ChIP/RNAi approach to the identification of EWS-FLI1 target genes in its authentic cellular context. However, it will be necessary to validate each individual gene isolated from our screen for consistency of the presence or absence of expression in a panel of ESFT and further confirm binding of and regulation by EWS-FLI1 independently in order to determine those genes which may be of general importance to ESFT pathogenesis. So far, our results lay the basis for detailed functional studies downstream of EWS-FLI1 to unravel the pathogenetic processes resulting in ESFT development.
Materials and methods
Chromatin immunoprecipitation
STA-ET-7.2 cells were grown on fibronectin-coated plastics. A total of 8 Â 10 7 cells were harvested by trypsin/EDTA treatment and resuspended in 30 ml growth medium. After crosslinking for 15 min in 1% formaldehyde, cells were washed twice with ice-cold phosphate-buffered saline containing protease inhibitors (complete tablets; Roche Diagnostics, Vienna, Austria). Cells were lysed for 10 min on ice in 400 ml SDS lysis buffer containing protease inhibitors. Lysates were sonicated on ice to give chromatin fragments of approximately 200-1000 bp, and centrifuged and diluted to 1 ml with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl). Preclearing of lysates was performed for 30 min at 41C using 100 ml Protein G Sepharoset 4 Fast Flow (Amersham Biosciences, Vienna, Austria) blocked with tRNA and bovine serum albumin. Subsequently, the sepharose beads were pelleted and 100 ml protein G sepharose preincubated with 5 ml rabbit polyclonal Fli-1 C-19 or 5 ml KAI-1 C-16 antibodies (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA), or no antibody was added to the supernatant. First-round ChIP was performed overnight at 41C on a rotating wheel. Immunoprecipitates were washed once in low salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), once in high salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl), and twice in TE. Chromatin complexes were eluted from the protein G sepharose using 200 ml elution buffer (1% SDS, 0.1 M NaHCO 3 ) for 30 min under agitation. For each antibody, an aliquot of 15 ml of the ChIP reaction was mixed with 2 Â SDS sample buffer for SDS-PAGE analysis, and the efficiency and specificity of the ChIP reaction was monitored on Western blots probed with FLI1 C19 antibody (not shown). The major fraction of the eluates were diluted with ChIP dilution buffer and split into four aliquots, which were subsequently incubated at 41C overnight with protein G sepharose-bound antibodies FLI1 C-19, EWS 139/2 (a kind gift from CT Denny, UCLA, Los Angeles, Ca USA), KAI-1 C-16 and no antibody for a second round of precipitation. After repeated washings in low and high salt buffers and TE, precipitated chromatin was eluted into 150 ml elution buffer. The eluates were incubated with 8 ml of 5 M NaCl at 651C for 5 h, followed by proteinase K and RNaseA treatment in the presence of 4 ml of 0.5 M EDTA and 8 ml 1 M Tris-HCl (pH 6.5) at 451C for 30 min to reverse the crosslinks and release the genomic DNA from immunoprecipitated chromatin complexes. The DNA was recovered by phenol/chloroform extraction and ethanol precipitation with glycogen as an inert carrier overnight at À201C. DNA pellets were dissolved in 40 ml sterile H 2 O. To validate the efficiency of the dual ChIP reaction, PCR for the presence of TGFbR2 promoter sequences, an established direct target of EWS-FLI1, was performed after the second round of precipitation and resulted in specific signals exclusively in the samples obtained by the EWS-FLI1-specific antibodies (not shown). No signals were obtained using primers for an irrelevant gene (b2 microglobulin). This result served as a surrogate for the enrichment of EWS-FLI1-specific genomic sequences in the precipitated protein-DNA complexes. Further analysis of EWS-FLI1-bound DNA was performed on pooled second-round ChIP samples.
Shot-gun cloning of chromatin-associated DNA DNA precipitated by ChIP was digested with Sau3AI (Amersham Biosciences, Vienna, Austria) in 30 ml overnight at 371C. Water was added to a total volume of 200 ml before phenol/chloroform extraction. After the addition of 4 ng of BamH1 digested and dephosphorylated pBluescript (Stratagene, Amsterdam, The Netherlands), the DNA was precipitated and ligated to the vector using T4 DNA ligase (Promega, Mannheim, Germany) overnight and transformed into Escherichia coli JM109 cells (Promega). Inserts of a size larger than 150 bp were sequenced.
PCR on ChIP products
PCR reactions were performed using DyNAZymet II DNA polymerase (Finnzymes, Espoo, Finnland). As template, 1 ml of chromatin immunoprecipitated DNA or input DNA was used. Amplification was performed with 40 cycles consisting of denaturation at 951C, annealing at 601C, and extension at 721C for 30 s each. Forward and reverse primers for TGFbR2 were GTGTGGGAGGGCGGTGAGGGGC and GAGGGA AGCTGCACAGGAGTCCGGC, for ACCN1 CCTCTCCTT CTCTGTCTGATC and GCAGCTCAGGCCCTATCATC, for TCF12 CCAGTTGCCTGAAGTATCTATC and CTCAC TCATTAATTAATCTCCTGC, for PFTK1 5 0 -CAAGCAG GAGGTAGTTTAAGGC and GGCAGTTGCCTCAGATT CTCAC, and for MK-STYX GAACATTCAACTCCAGAG GAGG and CTCTCAGTTACAAGACAGAGGAG.
RNA interference
Suppression of EWS-FLI1 in ESFT cells by RNAi was accomplished using a pSUPER-based retroviral shRNA expression system as described in (Brummelkamp et al., 2002) . Two vectors were constructed targeting the sequence CACCCACGUGCCUUCACAC in the FLI1 3 0 coding region (EF4), and GCUACGGGCAGCAGAGUUC overlapping the fusion region of type 2 ews-fli1 RNA (EF22). For EF4, a mismatched control EF4M was designed (CACCCACGGUC CUUCACAC). To target the fusion region of type 1 ews-fli1, a previously published siRNA sequence was used (Dohjima et al., 2003) (designated EF30 in the context of this manuscript), which also served as a mismatched control in experiments targeting type 2 ews-fli1 RNA. siRNA sequences were converted to shRNA expression cassettes, cloned into the retroviral self-inactivating virus pSuperRetro (pSR) (a gift from R Agami, The Netherlands Cancer Institute, Amsterdam, The Netherlands), and amphotropic retroviral stocks were prepared from the Phoenix packaging cell line Pro-Pak-A.52 (ATCC, Rockville, MD, USA) 2 days after transfection with LipofectAMINE Plus reagent (Invitrogen, Groningen, The Netherlands). STA-ET-7.2 cells were infected with 1 : 3 diluted supernatant of the packaging cell line and subjected to puromycin selection 1 day after infection. Cells were either maintained as monolayer cultures or plated into 0.35% soft agar 2 days after the start of puromycin selection. Multiplex PCR for ews-fli1 and gapdh RNA expression was performed with ews-fli1 primers TCCTACAGCCAAGCTCCAAGTC and ACTCCCCGTTGGTCCCCTCC and gapdh primers TGAAGGTCGGAGTCAACGGATTTGGT and CATGTG GGCCATGAGGTCCACCAC in a competitive PCR reaction consisting of 25-35 amplification cycles of 30 s at 941C, 1 min at 651C, and 1 min at 721C. Semiquantitative RT-PCR for induction of tgfbr2 expression was performed with primers TTGCTCACCTCCACAGTGATC and GAGCCGTCTTCA GGAATCTTC in 30 cycles of 1 min at 951C, 1 min at 581C, and 2 min at 721C.
Gene expression profiling
Changes in gene expression profiles of ESFT cells upon knock down of EWS-FLI1 by RNAi were followed on Affymetrix HG-U133A and B GeneChips s (Affymetrix Inc., Santa Clara, CA, USA). cRNA target synthesis and GeneChip s hybridizations, washing and staining steps, scanning, and data analysis (MAS 5.0, MicroDB 3.0, DMT 3.0) were carried out according to standard protocols recommended by the manufacturer (Affymetrix Inc., Santa Clara, CA, USA) and performed by the local Affymetrix Service Provider (VBC-Genomics Research GmbH, Vienna, Austria). Differences in signal intensities on Affymetrix chips between control-infected and shEFsuppressed ESFT cells were considered as representative for altered gene expression only if detection P-values for present calls were below 0.05 in all three experiments. Gene expression was considered induced or repressed if change in P-values were o0.006 and >0.994, respectively, in all three comparative RNAi experiments performed.
To correlate this set of up-and downregulated genes with expression data obtained by the microarray-based comparison of ESFT versus non-ESFT cell lines (HGU95Av2, Affymetrix Inc., Santa Clara, CA, USA; Schaefer et al., 2004) , the data set of the latter study was also dichotomized. For this purpose, the median expression value of seven ESFT cell lines was divided by the median expression of six osteosarcoma, six clear-cell sarcoma of soft parts, and eight neuroblastoma samples. Genes showing ratios greater than 1.00 were considered 'specifically overexpressed in ESFT', while values less than 1.00 define genes 'specifically underexpressed in ESFT'. If a gene was represented by more than one probe set on the U95A-chip mean values across these probe sets were calculated first. The overall correlation between sets of genes either suppressed by EWS-FLI1 silencing and overexpressed in ESFT or induced by EWS-FLI1 silencing and underexpressed in ESFT was calculated using the w 2 test.
Direct EWS-FLI1 target genes
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Electromobility shift assay
Recombinant GST-EWS-FLI1 fusion protein and cellular extracts were generated as described earlier (Spahn et al., 2002) . For immunopurification of endogenous EWS-FLI1, cell extracts were prepared from 3 Â 10 7 cells (SK-N-MC and STA-ET-7.2). FLI1 antibody (15 ml) (Santa Cruz Biotech., Santa Cruz, CA, USA) was chemically crosslinked to 100 ml sheep anti-rabbit-coupled magnetic dynabeads s (Dynal Biotech ASA, Oslo, Norway) using dimethyl pimelinediimidate dihydrochloride (Sigma-Aldrich, St Louis, MI, USA) as a crosslinking agent. Immunoprecipitations were carried out overnight at 41C, and the precipitate was washed five times with lysis buffer. EWS-FLI1 was eluted into 40 ml of 100 mM glycine/HCl (pH 2) and the eluate was neutralized with 1 M Tris/HCl (pH 9), of which 10-20 ml were used for EMSA.
A measure of 10 ng of Factor Xa-digested recombinant EWS-FLI1 or immunopurified EWS-FLI1 was incubated with 15 000 c.p.m. of 32 P-labeled double-stranded oligonucleotides in 20 ml binding buffer (20 mM HEPES, pH 7, 2.6 mM MgCl 2 , 5% glycerol, 40 mM KCl, 100 mM EDTA, 0.1% NP-40) for 30 min at room temperature. For supershifts, 3 ml of undiluted FLI1 Hyb7.3 hybridoma supernatant was used. Competition experiments were performed in the presence of a 100-fold excess of unlabeled double-stranded oligonucleotides, which were added to the reaction 15 min prior to the labeled probe. Samples were separated on a 5% nondenaturing PAA gel in 0.5 Â TBE at 41C. The sequences for the TGFbR2 and MK-STYX probes are presented in Figure 6a .
Real-time PCR
Reactions were set up in a total volume of 25 ml containing 12.5 ml 2 Â Universal Master Mix, including ROX-reference dye and uracil N 0 -glycosylase (Applied Biosystems, Vienna, Austria) and AmpliTaq Gold DNA polymerase (PerkinElmer, Boston, MA, USA), 300 nM (TGFbR2) or 900 nM (EWS-FLI1, MK-STYX) of primers, 100 nM (MK-STYX) or 200 nM (EWS-FLI1, TGFbR2) of TaqMan probe, and 1 ml of cDNA template. The mixtures were prepared in 96-well optical microtiter plates and amplified on the ABI 7700 or 7900 Sequence Detection System using the following cycling parameters: 2 min at 501C, 10 min at 951C, and 50 cycles of 15 s at 951C and 60 s at 601C. Primer and probe sequences were as follows: for EWS-FLI1 CAGCCAAGCTCCAAGTCAA TATAG, AGGTTGTATTATAGGCCAGCAGTGA, and 6-FAM-CTCCTACCAGCTATTCCTCTACACAGCCGACTT AMRA; for TGFbR2 TCGTCCTGTGGACGCGTAT, TG TCAGTGACTATCATGTCGTTATTAACC, and 6-FAM AGCACGATCCCACCGCACGTTC-TAMRA; for MK-ST YXCACTGCCCTTCGAGTGAAGAA, GTTGTTATCATA CACCACGCAGTACTT, and 6-FAM-TGAATATCTTCTC CCGGAGTCTGTGGACC-TAMRA; and for b2M TGAG TATGCCTGCCGTGTGA, ACTCATACACAACTTTCAG CAGCTTAC, and 6-FAM-CCATGTGACTTTGTCACAGC CCAAGATAGTT-TAMRA.
Reporter gene assays
Wild-type and mutant 163 bp MK-STYX fragments were cloned into pGL3-promotor vector (Promega, Mannheim, Germany). An MK-STYX genomic fragment carrying a mutant mk2-2 site was assembled from two overlapping fragments, each generated by PCR combining MK2-2m sequences (Figure 5a) as either reverse or forward primer with forward and reverse primers from the end of the 163 bp MK-STYX fragment including Kpn1 and Xho1 restriction sites (TACGGTACCGATCCCTTGCCTTGGAATCAG and CCGCTCGAGGATCTATTCACTGTCCCCTGA). Neuroblastoma cells SJ-NB-7 (provided by T Look, St Jude Children's Research Hospital, Memphis, TN, USA) were transfected in 24-well plates in quadruplicates with 50 ng pGL3-promotor-MK-STYX wild-type or mutant vectors and 150 ng of empty pCMV-FM plus pCMV-FM-EWS-FLI1 expression vectors (Spahn et al., 2002) in different ratios as indicated and incubated in the absence or presence of 0.2 mM of the general caspase inhibitor z-VAD.fmk (Bachem, Bubendorf, Switzerland) for 24 h. For shRNA repression of EWS-FLI1-mediated MK-STYX activation, STA-ET-7.2 cells were transfected with 25 ng of reporter vector pGL3-promotor-MK-STYX, 25 ng of empty pCMV-FM vector or pCMV-FM-EWS-FLI1 expression vector, and 200 ng of pSR, shEF4, or the mismatch control shEF4M in quadruplicates. In all reporter gene experiments, 50 ng of an EGFP expression vector was included into one of the quadruplicates to monitor transfection efficiencies by flow cytometry. The remaining triplicates were measured for luciferase activity using BrightGlo Luciferase Assay System (Promega, Madison, USA) 24 h after transfection.
